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Integrated Transcriptomics 
Establish Macrophage Polarization 
Signatures and have Potential 
Applications for Clinical Health and 
Disease
Matheus Becker1,2,*, Marco A. De Bastiani1,2,*, Mariana M. Parisi3,*, Fátima T. C. R. Guma4, 
Melissa M. Markoski5, Mauro A. A. Castro6, Mark H. Kaplan7, Florencia M. Barbé-Tuana3,8 & 
Fábio  Klamt1,2
Growing evidence defines macrophages (Mϕ) as plastic cells with wide-ranging states of activation 
and expression of different markers that are time and location dependent. Distinct from the simple 
M1/M2 dichotomy initially proposed, extensive diversity of macrophage phenotypes have been 
extensively demonstrated as characteristic features of monocyte-macrophage differentiation, 
highlighting the difficulty of defining complex profiles by a limited number of genes. Since the 
description of macrophage activation is currently contentious and confusing, the generation of 
a simple and reliable framework to categorize major Mϕ phenotypes in the context of complex 
clinical conditions would be extremely relevant to unravel different roles played by these cells 
in pathophysiological scenarios. In the current study, we integrated transcriptome data using 
bioinformatics tools to generate two macrophage molecular signatures. We validated our signatures 
in in vitro experiments and in clinical samples. More importantly, we were able to attribute 
prognostic and predictive values to components of our signatures. Our study provides a framework 
to guide the interrogation of macrophage phenotypes in the context of health and disease. The 
approach described here could be used to propose new biomarkers for diagnosis in diverse clinical 
settings including dengue infections, asthma and sepsis resolution.
Macrophages (Mϕ ) are pivotal cells of the immune system that participate in pleiotropic actions1. 
Microenvironmental signals promote the development of Mϕ subsets that secrete specific cytokines and 
perform distinct functions in regulating and resolving immunity, perpetuation of inflammation2–5, or 
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as lately suggested regulating blood supply and metabolism6,7. Sub-populations of Mϕ exist within a 
continuum of diverse interchangeable phenotypic spectrums designated in the literature for simplicity as 
M1 (classically activated), or M2a, M2b and M2c (collectively termed alternatively activated). They have 
overlapping functions that can be modulated by inducers including hematopoietic growth factors and 
cytokines (e.g.: Macrophage Colony Stimulating Factor (M-CSF) or Granulocyte Macrophage Colony 
Stimulating Factor (GM-CSF)) or small metabolites such as glucose, lipids or sodium chloride2,8–13. To 
add more complexity to this issue, Mϕ exhibit plasticity across various diseases and can switch their 
phenotype depending on the in vivo environment and stage of the disease. As an example, more than 
9 different gene signatures based on distinct spectrum of transcriptional programs have been described 
recently for human macrophages14. Moreover, the inconsistency found in the diversity of terminology, 
activation inducers and markers used to describe Mϕ subsets, enhance the complexity when compari-
sons of different studies are required for consensus15.
Since different Mϕ subsets are profoundly involved in the development and outcome of many of the 
so called “Western diseases” (e.g.: autoimmune diseases, atherosclerosis, cancer, microorganisms infec-
tions and asthma) and are key cells in controlling normal physiological processes2,5,16–20, here we question 
whether a restricted set of marker molecules could be helpful to define a particular functional phenotype 
encountered in the context of diseases. With this in mind, the presence of a minimum set of specific 
markers that describe a particular phenotype dependent on the inducers used to generate the Mϕ , could 
be seen as a valuable tool to classify and study defined Mϕ subsets found in a specific context, in order 
to develop precise targeted Mϕ immunotherapies.
In the present study we explored the use of bioinformatics’ tools to analyze published transcriptome 
data in predefined in vitro conditions for Mϕ activation. A robust phenotype signature, herein named 
M(IFNγ + LPS, TNFα ) and M(IL-4, IL-13), was obtained from the analysis of responsive genes in three 
pre-selected datasets where human monocyte-derived macrophages (MDM) were challenged under clas-
sical activators (IFNγ + LPS, TNFα ) or alternative inducers (IL-4 or IL-13). The expression of some 
selected markers was confirmed by real time quantitative polymerase chain reaction (RT-qPCR) in in 
vitro MDM derived from healthy human peripheral blood mononuclear cells (PBMC) and in commonly 
used differentiated human cell lines (THP-1 and U-937). Finally, we validated our list using independent 
original microarray datasets of clinical cohorts in the context of different diseases. In this regard, we were 
able to attribute a minimum set of molecular biomarkers that corresponded to defined Mϕ phenotypes 
among milieus of specific diseases. Our signatures effectively identified classically M(IFNγ + LPS,TNFα ) 
and alternatively M(IL-4, IL-13) activated Mϕ in clinical controlled sets. More importantly, we demon-
strated prognostic and predictive values of selected biomarkers associated with diseases in diverse clinical 
settings such as dengue infections, asthma and sepsis resolution.
Results
Generation of M(IFNγ + LPS,TNFα) and M(IL-4, IL-13) Gene Signatures. Heterogeneous 
sources of cells, experimental inducers and markers are used to describe phenotypes and responses 
of polarized Mϕ creating an enormous amount of conflicting data15. To systematically evaluate data 
from defined experimental conditions, as classically and alternatively activated Mϕ , we specifically chose 
in vitro datasets reporting explicit description of experimental standard conditions. In this regard, we 
integrated gene expression profiling from three independent human datasets (GSE509921; GSE3544922; 
GSE3653723) that used peripheral blood mononuclear cells as the source for differentiation into MDM 
with M-CSF and polarized in vitro with IFNγ + LPS or TNFα , IL-4 or IL-13 (Supplementary Table S1). 
The protocol design is illustrated in Fig. 1A.
Using GEO2R tool analysis in each selected dataset we obtained two differentially expressed gene 
signatures that we termed the M(IFNγ + LPS, TNFα ) and M(IL-4, IL-13) phenotypes (Fig. 1B), follow-
ing the guidelines recently suggested by Murray et al.15. Afterward, with an inclusion criteria of P value 
≤ 0.0001 (Fig.  1B, vertical line is the cut-off) and presence in all three datasets (red dots in Fig.  1B), 
our selection resulted in 106 M(IFNγ + LPS, TNFα ) and 58 M(IL-4 or IL-13) differentially expressed 
genes (Supplementary Table S2 and S3). Finally, signatures of both phenotypes were depicted as graphic 
models with nodes representing gene products, clustered according to seven previously reported func-
tional subdivisions15. (Fig. 1C). These gene signatures are comprised of established enzymes (ALOX15), 
cytokines (TNFα and TGFβ), chemokines (CCL13, CCL17, CXCL9 and CXCL10), receptors and tran-
scription factors (STAT1), and less explored genes such as LAG-3 (lymphocyte-activation gene 3), 
LAMP3 (lysosomal-associated membrane protein 3), FZD2 (frizzled class receptor 2) and CLIC2 (chlo-
ride intracellular channel 2) among others. In order to illustrate differential gene expression responses 
to inducers, the obtained M(IFNγ + LPS, TNFα ) and M(IL-4, IL-13) gene networks were subsequently 
plotted as representative topological responses using landscape analysis with ViaComplex® software24. X 
and y-axis represent gene signature networks and the z-axis indicates an illustrative expression response 
to IFNγ + LPS or IL-4 inducers (Fig. 1C).
In Vitro Validation of M(IFNγ + LPS, TNFα) and M(IL-4, IL-13) Gene Signatures. To experi-
mentally validate our in silico Mϕ signatures, we used standard M-CSF conditions to differentiate human 
Mϕ from peripheral CD14 + blood monocytes obtained from five healthy donors. These cells were acti-
vated/polarized into the M(IFNγ + LPS) or M(IL-4) phenotypes. Figure 2A (left) shows RT-qPCR results 
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Figure 1. Macrophage phenotypes signatures construction and gene network representation. (A) Protocol 
design for M(IFNγ + LPS, TNFα ) and M(IL-4, IL-13) gene signatures. (B) Volcano plots representation 
of differential expression analyses. Red dots are genes present in all three datasets with adjusted P value 
≤0.0001. (C) M(IFNγ + LPS, TNFα ) and M(IL-4, IL-13) gene networks (left) and their illustrative 
topological representation (landscape analysis) showing changes in relative gene expression after IFNγ + LPS 
or IL-4 stimuli (right) (see Supplementary Table S2 & S3 for the complete list of retrieved genes).
www.nature.com/scientificreports/
4Scientific RepoRts | 5:13351 | DOi: 10.1038/srep13351
Figure 2. In vitro validation of selected genes from M(IFNγ + LPS, TNFα) and M(IL-4, IL-13) 
signatures. (A) RT-qPCR from human MDM activated with 50 ng/mL of M-CSF for 7 days and stimulated 
with IFNγ (20 ng/mL) + LPS (100 ng/mL) or IL-4 (20 ng/mL) for additional 18 h. (B) RT-qPCR from THP-1 
(human acute monocyte leukemia cell line) differentiated with 20 ng/mL PMA for 3 days and stimulated 
with IFNγ (20 ng/mL) + LPS (100 ng/mL) or IL-4 (20 ng/mL) for additional 24 h. Data represent median and 
IQR (interquartile range) of five independent experiments normalized to TATA binding box protein (TBP). 
Data was considered statistically significant for *(P ≤ 0.05) and ** (P ≤ 0.01) (Mann-Whitney U test).
www.nature.com/scientificreports/
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from MDM stimulated with IFNγ + LPS. In agreement with the literature, we observed increased expres-
sion of selected targets of M(IFNγ + LPS, TNFα ), such as CXCL9, CXCL10, IL-1β, IL-15, STAT1 and 
TNFα. In the same way, RT-qPCR analysis of IL-4-induced MDM revealed increased expression of the 
selected targets of M(IL-4, IL-13), such as ALOX15, CXCL13, CXCL17 and F13A1, with no significant 
upregulation of TGFβ (Fig. 2A). Similar results were obtained from the cultured THP-1 cell line (Fig. 2B) 
and U-937 cells (manuscript in preparation).
Application of M(IFNγ + LPS, TNFα) and M(IL-4, IL-13) Signatures to Discriminate Clinical 
Settings and Controlled Conditions. To evaluate the robustness of our gene signatures in discrim-
inating between macrophage phenotypes, we analyzed the performance of our M(IFNγ + LPS, TNFα ) 
and M(IL-4, IL-13) gene signatures in datasets from previously published studies that used controlled 
clinical conditions with the GSEA tool. Table 1 summarizes the description of the selected clinical studies 
where a macrophage polarization phenotype could be expected: i) the classically activated phenotype, 
using retrieved macrophages from bronchoalveolar lavage (BAL) in patients treated with lipopolysac-
charide (LPS) (GSE4088525) and ii) the alternatively activated phenotype, using lung biopsies from asth-
matic patients (GSE4164926). As expected, genes from the M(IFNγ + LPS, TNFα ) set were significantly 
enriched in the LPS treated group (Fig. 3A). In addition, enrichment analysis of the asthmatic subjects 
was also significant in the M(L-4, IL-13) signature (Fig.  3B). Figure  3A,B (right) illustrate differential 
gene expression responses of the M(IFNγ + LPS, TNFα ) and M(IL-4, IL-13) gene networks in both 
conditions. These results are consistent with the role played by LPS-induced IFNγ in pro-inflammatory 
macrophages or IL-4 driving an alternative activation state in the clinical context of asthma12,27,28.
We also tested 8 additional GEO datasets that used in vitro MDM or human cell lines under con-
trolled culture environment, retrieving the expected results from polarization. As expected and in light 
of our findings, the M(IFNγ + LPS, TNFα ) signature was enriched in genes altered under intracellular 
parasites and bacterial, or viral infection, as well as under pro-inflammatory conditions (LPS or IFNγ ). 
By contrast, the M(IL-4, IL-13) gene signature was enriched in the context of IL-4, IL-10 or IL-13 stim-
ulation (Supplementary Table S4).
Together, our results indicate that our macrophage signatures could characterize microarrays from in 
vivo specific pathological scenarios that take into account the complexity of the tissue components, as 
well as in in vitro factors that impact cultured primary human cells and human cell lines.
Disease Outcomes Predictions and Functional Correlation in Complex Clinical Pathologies. 
As macrophages play a key role in determining the activation or resolution of immune responses and can 
determine the fate of a disease29, we evaluated the capacity of our macrophage phenotype signatures to 
anticipate the patient outcome or response to specific drug treatment (prognostic and predictive behavior 
of markers) based on the enrichment analysis of selected genes. We asked whether our M(IFNγ + LPS, 
TNFα ) signature could be used to predict the complication of dengue infection into a hemorrhagic out-
come, the drug response in HIV positive patients, and sepsis resolution in children.
To do so, we considered new microarray datasets in order to first identify a responsive set of genes 
presented in our macrophage signatures clustered by different pro-inflammatory scenarios (e.g.: viral 
and bacterial infections). We retrieved 6 datasets derived from viral and 6 from bacterial infections 
(Supplementary Table S5). For each analysis set, based on GSEA, we obtained a significant responsive 
gene list, considering an inclusion criterion for genes present in the core enrichment in more than 80% 
of cases. This procedure retrieved 12 genes in our M(IFNγ + LPS, TNFα ) signature responsive to viral 
and 35 genes to bacterial infections (protocol design presented in Fig. 4A). With the virus and bacteria 
gene lists, we performed logistic regression analyses in order to associate gene expression with different 
disease outcomes. In this regard, we expressed our results as odds ratio (OR), which typically represents 
a measure of association between a predictor and an outcome. In our settings, a particular gene and a 
specific disease outcome prediction (e.g.: live versus death, disease severity or treatment response).
GEO ID Cohort Description Experimental Groups Reference
GSE40885
Sterile saline was instilled into a lung segment 
by bronchoscope, followed of instillation of 
LPS into the contralateral lung for 6 hours. 
After, a bilateral bronchoalveolar lavage was 
performed and transcriptional profiling was 
done on alveolar Mϕ .
Alveolar Mϕ from 
saline (n = 7) vs. LPS-
treated (n = 7).
Reynier, F. et al. Gene expression profiles 
in alveolar macrophages induced by 
lipopolysaccharide in humans. Molecular 
Medicine 2012 (18):1303–1311.
GSE41649 Transcriptional profiling of bronchial biopsy of healthy and asthmatic subjects.
Healthy (n = 4) vs. 
asthmatic patients 
(n = 4).
Chamberland, A. et al. A comparison of 
two sets of microarray experiments to 
define allergic asthma expression pattern. 
Experimental lung research 2009 (35): 
399–410.
Table 1.  Gene Set Enrichment Analysis (GSEA) of M(IFNγ + LPS, TNFα) and M(IL-4, IL-13) 
gene networks in clinical samples. Abbreviations: IFNγ , interferon-gamma; IL-4, interleukin-4; IL-13, 
interleukin-13; LPS, lipopolysaccharide; Mϕ , macrophages; TNFα , tumor necrosis factor-alpha.
www.nature.com/scientificreports/
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As depicted in Fig. 4A, when comparing controlled versus hemorrhagic dengue (GSE18090, unpub-
lished data), we found that the individual expression of ISG15, OASL, OAS2 and TNFSF10 can be used 
to anticipate the complication status of dengue infection into a hemorrhagic outcome. Further combined 
analyses when all 4 genes were tested altogether was not able to improve OR. Similarly, the expression 
of IFITM1 can discriminate the response of patients to HIV treatment (GSE5290030). From our bac-
terial infection list, we found that the expression of CD40 was a predictor of death in septic children 
(GSE2644031).
We then searched for clinical conditions that could benefit from the same experimental approach 
using genes associated with the M(IL-4, IL-13) phenotype, such as asthma and pulmonary fibrosis 
Figure 3. Validation of M(IFNγ + LPS, TNFα) and M(IL-4, IL-13) signatures under controlled clinical 
settings. (A) M(IFNγ + LPS, TNFα ) signature response of alveolar macrophages after LPS instillation in 
the lung based on Gene Set Enrichment Analysis (GSEA) (left) and topological representation (landscape 
analysis) (right). (B) M(IL-4, IL-13) signature response of bronchial biopsy from asthmatic patients based on 
GSEA (left) and landscape analysis (right).
www.nature.com/scientificreports/
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(Supplementary Table S6), and constructed another list of genes with the GSEA tool (Fig.  4B). Data 
analysis enabled 2 comparisons and setup a threshold of 2/2 retrieved genes to be in the final list. In this 
new list, we obtained 7 genes. We performed logistic regression analyses and compared healthy versus 
severe asthmatic patients (GSE27876, unpublished data). We found that the expression of RAMP1 was 
associated with the severity of asthma. In the same way (GSE4369632), the expression of three other genes 
FSCN1, PSTG1 and SPINT2 revealed an association with the development of severity of asthma (Data is 
summarized in Fig. 4B). Importantly, in all the 6 clinical datasets tested, we found a consistency in that 
the specified expressed genes were predicted by our created list M(IFNγ + LPS, TNFα ) or M(L-4, IL-13).
Discussion
Growing evidence defines macrophages as plastic cells with wide-ranging states of activation and con-
comitant expression of different markers, which are time and location dependent2,33. Because of pleio-
tropic actions of signaling through recognition receptors, secretion of cytokines, their essential role in 
activation of immunity or in resolution and the relation to disease outcome, published data has identified 
macrophages as key players in tissue homeostasis. Indeed, different from the initially proposed M1/M2 
dichotomy34, plasticity and diversity have been extensively demonstrated as characteristic features of 
monocyte-macrophage differentiation15,33,35,36, pointing to the difficulty on defining complex profiles by 
a small and limited number of genes33. In this regard, conflicting and oversimplified data have been used 
to define different subsets. Thus, the generation of a simple and reliable framework to categorize major 
Mϕ phenotypes in the context of complex clinical conditions would be extremely relevant to unravel 
different roles played by these cells in pathophysiological scenarios.
In the current study, we integrated transcriptome data using bioinformatics tools to generate gene 
expression profiling of macrophages, activated under precise and specific conditions, and created two mac-
rophage molecular signatures from specific defined in vitro induced phenotypes, namely M(IFNγ + LPS, 
TNFα ) and M(IL-4, IL-13). In line with these findings and the complexity associated with a wide range 
Figure 4. Prognostic and predictive values of selected components derived from M(IFNγ + LPS, TNFα) 
and M(IL-4, IL-13) signatures in complex clinical settings. Protocol design to select consensus responsive 
genes in infectious (A) and non-infections (B) conditions to interrogate different clinical datasets. The 
input lists for the consensus analysis comprised of 106 M(IFNγ + LPS, TNFα ) and 58 M(IL-4, IL-13) genes. 
M(IFNγ + LPS, TNFα ) list was interrogated for association with viral and bacterial (6 independent gene 
expression signatures each) infections, retrieving 12 and 35 consensus gene markers, respectively. M(IL-4, 
IL-13) list was interrogated for association with non-infectious conditions (2 independent gene expression 
signatures), retrieving 7 consensus gene markers (see Supplementary Table S5 & S6 for the complete 
description of datasets). Prognostic or predictive values of these markers were assessed by logistic regression 
analysis using selected clinical cohorts. Data were expressed as Odds Ratio (OR). (Drawings made by F. M. 
B-T).
www.nature.com/scientificreports/
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of evidence not easy to summarize, we validated our macrophage molecular signatures in vitro and in 
clinical samples from published microarray data. More importantly, we were also able to attribute prog-
nostic and predictive values to some components of our signatures.
As expected, our study confirms that pro-inflammatory inductors such as IFNγ , LPS and TNFα are 
able to induce a macrophage phenotype distinct from that induced by cytokines as IL-4 and IL-1314,15,37. 
We confirmed the expression of well-established markers of classically (e.g., CD80, CXCL9, CXCL10, 
IL-15, ITGAL, TNFS10 and STAT1) and alternatively (e.g., ALOX15, CCL13, CCL17, F13A1, PTGS1) acti-
vated macrophages markers that support the validity of our gene lists. In addition, our strategy retrieved 
several genes not previously used as M(IFNγ + LPS, TNFα ) or M(IL-4, IL-13) markers that could be 
explored in the macrophage biology field.
In this regard, unexplored gene markers such as LAG-3, LAMP3, OPTN (optineurin) and PIN-1 
(peptidylprolyl cis/trans isomerase, NIMA-interacting 1) were highlighted in the M(IFNγ + LPS, TNFα ) 
molecular signature. For example, LAG-3 is a high affinity ligand for MHC class II originally identi-
fied as a T and B-lymphocyte cell marker38,39. So far, no data has been shown describing its expres-
sion in circulating monocytes or activated macrophages. Activated LAG-3 + lymphocytes present at 
sites of inflammation may reduce the differentiation of monocytes into macrophages or fully competent 
antigen-presenting dendritic cells, thus limiting the magnitude of the ongoing T-cell immune responses40. 
However, analysis of gene expression from three independent datasets (GSE21548, GSE28785, GSE29628) 
derived from pure monocytes cell lines (RAW264.7 and THP-1) from two different species (mouse and 
humans) showed consistently expression of LAG-3. At this point we cannot exclude the possibility that 
LAG-3 expression could be from contaminating cells in all three datasets, such as T and B lymphocytes, 
rather than from macrophages. Another newly classified gene was LAMP3, a well-established marker 
of mature dendritic cells41. Also, OPTN has a known role in vesicle trafficking and bacterial handling. 
However, their expression and role in human M(IFNγ + LPS, TNFα ) macrophages remains unexplored. 
Interestingly, a recent work described the association of pro-inflammatory cytokine release deficiency in 
macrophages with reduced OPTN expression in a subset of patients with Crohn’s disease42. Finally, we 
were not able to find any study addressing the association between PIN-1 and macrophages. As these 
examples, several other genes retrieved in the M(IFNγ + LPS, TNFα ) list have not yet been explored as 
potential macrophage markers. Thereby, our list suggest a great variety of genes to be studied and used 
as new M(IFNγ + LPS, TNFα ) macrophage markers.
In addition, the M(IL-4, IL-13) molecular signature retrieved genes such as FZD2, CLIC2, EMILIN2 
(elastin microfibril interfacer 2), CDR2L (cerebellar degeneration-related protein 2-like), CMTM8 
(CKLF-like MARVEL transmembrane domain containing 8) that has not been fully explored as potential 
human macrophage markers. In this sense, FZD2 has a potential role in macrophage-regulated angio-
genesis, as proposed by Newman et al.43. CLIC2 is a chloride intercellular channel that is not reported 
as M(IL-4, IL-13) marker, but few evidences suggest that nuclear translocation of CLIC4 regulates mac-
rophage deactivation44. Another poorly explored gene in human macrophages, EMILIN2 gene was not 
explored, but one study with mouse macrophages established a correlation between EMILIN2 protein 
and thrombosis45. Finally to our knowledge, there are no association between CDR2L and CMTM8 genes 
and macrophages.
Because we were interested in exploring the potential application of our framework in profiling mac-
rophages’ phenotypes, we generated logistic regression models to associate the consensus markers with 
diseases outcomes. In this regard, we show that a set of selected markers is able to predict patients’ out-
comes when dissimilar pathologies were grouped according to infectious (e.g.: dengue, HIV, and sepsis) 
or non-infectious conditions (e.g.: asthma) (Fig. 4).
Our initial analysis of viral infection responsive genes derived from our M(IFNγ + LPS, TNFα ) sig-
nature retrieved TNFSF10, ISG15, OAS2 and OASL. For example, we found that the expression levels 
of TNFSF10 (tumor necrosis factor (ligand) superfamily, member 10, commonly known as TRAIL), 
obtained from the M(IFNγ + LPS, TNFα ) signature, could discriminate the severe cases of hemorrhagic 
dengue. The protective role of TNFSF10, as apoptosis inducer, in dengue severity or symptoms’ com-
plications has already been identified46,47. Serum from patients with dengue had significantly increased 
TNFSF10 protein levels48. Its antiviral action has been demonstrated in various cells, including in ex vivo 
infected monocytes and macrophages49. Another gene that was shown to protect from dengue severity 
was Interferon-Stimulated Gene 15 (ISG15)50,51. Regardless, our logistic regressions analyses demonstrates 
that the expression of ISG15 can predict the course of dengue patients into a more severe outcome. 
Indeed, a recent published study52 with infected cultured cell lines implicated ISG15 in dengue virus 2 
replication inhibition. Moreover, two members of the OAS (2,5-oligoadenylate synthetase) gene family, 
OAS2 and OASL, also contribute to the antiviral response. Two recent studies have demonstrated an 
association between OAS2 haplotypes and differential susceptibility to clinical outcomes of dengue virus 
infection53,54. In addition, other members of the OAS gene family, as OAS1 p42, OAS1 p46, and OAS3 
p100 have been shown to have antiviral effects in dengue complication55. Therefore, these IFN-induced 
proteins may play important roles in the antiviral response and can be addressed as promising targets 
poorly explored in the literature for the management of dengue infection.
Other applications of our molecular signature could be to anticipate clinical response to treatment. 
In this aspect, we found that IFITM1 (interferon-induced transmembrane 1) is associated with better 
response to HIV treatment, presenting an OR of 9.4. IFITM1 has antiviral action already demonstrated in 
www.nature.com/scientificreports/
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highly pathogenic human virus56 and has been associated with cell-to-cell HIV-1 transmission57, but how 
IFITM1 contributes to treatment resistance is still unclear. We went further and analyzed the bacterial 
infection responsive genes derived from our M(IFNγ + LPS, TNFα ) signature and applied in predicting 
sepsis outcome. We found that the expression of CD40, a molecular target that had already been linked 
with inflammation58, have prognostic role for septic patients. Altogether these results emphasize the 
robustness of our genes signatures and demonstrate that our analysis framework was able to predict 
and validate the presence of already known genes or find new candidates to further explore association 
between expression, biological function and clinical outcome.
In the same context, we applied our M(IL-4, IL-13) signature to predict outcomes in asthma cohorts. 
Asthma is a heterogeneous disease that is classified phenotypically as mild, moderate, or severe59. We 
found that RAMP1, FSCN1, PSTG1 and SPINT2 genes could be associated with the development of 
severity of asthma. However, no studies showed an association of FSCN1 (fascin actin-bundling protein 
1) and SPINT2 (serine peptidase inhibitor, Kunitz type, 2) with the evolution of asthma severity.
In conclusion, we proposed a consensus collection of markers describing major macrophages’ acti-
vation phenotypes, namely M(IFNγ + LPS, TNFα ) and M(IL-4, IL-13), able to characterize robustly 
controlled in vitro and in vivo scenarios for macrophage induction. Since the description of macrophage 
activation is currently contentious and confusing15,33, our study provides a framework to guide the inter-
rogation of macrophage phenotypes in the context of health and disease. Despite further studies being 
necessary to understand the role played by retrieved genes, the approach described unraveled new gene 
candidate markers for diverse clinical settings such as dengue infections, asthma and sepsis resolution.
Methods
The methods were carried out in accordance with the approved guidelines.
Ethics. This study was approved by the Ethics Committee of PUCRS (No. 06/03537). All participants 
provided written informed consent for blood collection and research.
Microarray Datasets and Macrophage Phenotypes’ Signatures. Microarray expression profiles 
were extracted from public available Gene Expression Omnibus (GEO) NCBI database (http://www.ncbi.
nlm.nih.gov/geo/). The selected GSE datasets are presented in Supplementary Table S1. Search criteria 
included Medical Subject Heading (MeSH) terms for “monocytes-derived macrophages” and “Homo 
sapiens” and “macrophages polarization”.
GEO2R tool (www.ncbi.nlm.nih.gov/geo/geo2r) was used to identify differential gene expression to 
obtain classically activated M(IFNγ + LPS,TNFα ) and alternatively activated M(IL-4, IL-13) phenotypes 
signatures60. We extracted two lists of genes with a significant different expression in the two polarized 
Mϕ discrete phenotypes with adjusted P-value ≤ 0.0001 Student’s t-test and Benjamini & Hochberg 
false-discovery rate (FDR) correction. Finally, an integrated gene list for each phenotype was created 
where all the pre-selected differentially expressed genes that were consistently present in the three data-
sets were included (protocol design in Fig. 1A).
Gene Set Enrichment Analyses (GSEA) and Network Construction. We explored the robust-
ness of our gene signatures using GSEA method (http://www.broadinstitute.org/gsea/index.jsp)61. In this 
regard, genes are ranked based on the correlation between their expression and their class distinction, 
M1-like or M2-like, by using any suitable metric. In that case, the method evaluates if an a priori defined 
set of genes (e.g.: M(IFNγ + LPS, TNFα ) and M(IL-4, IL-13) gene signatures) is randomly distributed 
or is primarily associated with a tested class61. Expression networks of differential signatures graphs 
and illustrative landscape maps were constructed and edited using free academic Medusa® (https://sites.
google.com/site/medusa3visualization)62, and ViaComplex® (http://lief.if.ufrgs.br/pub/biosoftwares/via-
complex)24 softwares.
Logistic Regression. Logistic regression models associate binary responses with continuous varia-
bles. Specifically, we applied a bias-reduced logistic regression to test gene expressions against defined 
pathological outcomes in an attempt to identify promising markers from our macrophage signa-
tures. Firth’s penalized-likelihood logistic regression was originally developed to reduce the bias of 
maximum likelihood estimates and provide a good solution to monotone likelihoods (http://www.
meduniwien.ac.at/user/georg.heinze/techreps/tr2_2004.pdf) (http://www.jstor.org/stable/2336755?ori-
gin = JSTOR-pdf&seq = 1#page_scan_tab_contents). The regressions were modeled using R statistical 
environment (http://www.R-project.org).
Cell Cultures and Macrophage Differentiation. PBMC from healthy individuals (n = 5) were 
isolated by Histopaque® gradient (d = 1.077) (Sigma Aldrich, MO, USA) according to manufac-
turer’s instructions. Monocytes were purified from freshly isolated PBMC using monoclonal CD14 
antibody-conjugated microbeads (Miltenyc Biotec, Germany). Purity was >98%. Monocytes were cul-
tured in RPMI-1640 media (Invitrogen, CA, USA), supplemented with 10% heat-inactivated fetal bovine 
serum (FBS) (Invitrogen), 2 mM L-glutamine (Invitrogen), 100 U/mL penicillin and 100 mg/mL strep-
tomycin (Invitrogen) (RPMI 10% FBS) at 37 °C in 5% CO2 humidified air. For in vitro differentiation 
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of MDM, monocytes were incubated with RPMI (10% FBS) supplemented with Macrophage Colony 
Stimulating Factor (M-CSF) (50 ng/mL) (Peprotech, USA) for 7 days. For differential polarization, Mϕ 
were supplemented with IFNγ (20 ng/mL) (Peprotech, USA) and LPS (100 ng/mL) (Sigma-Aldrich) or 
IL-4 (20 ng/mL) (Peprotech, USA) for additional 18 h, respectively.
The THP-1 (human acute monocytic leukemia) and U-937 (human histiocytic lymphoma) cells lines 
were obtained from Rio de Janeiro Cell Bank (www.bcrj.org.br) and maintained in RPMI-1640 media 
as mentioned above. Cell lines were differentiated using phorbol 12-myristate 13-acetate (PMA) (Sigma 
Aldrich), 20 nM and 10 nM for THP-1 or U-937 cells, for 72 h. PMA treated cells were polarized for 
additional 24 h by incubation with IFNγ (20 ng/mL) + LPS (100 ng/mL) or IL-4 (20 ng/mL) or IL-13 
(20 ng/mL) for M(IFNγ + LPS), M(IL-4) or M(IL-13) phenotypes.
RNA Isolation and RT-qPCR. Gene expression analysis was performed using gene-specific prim-
ers designed with IDT Design Software (Integrated DNA Technologies Inc., CA, USA) (Supplementary 
Table S7). Total RNA (1.2 μ g) was isolated from M(IFNγ + LPS) and M(IL-4) cells using Trizol Reagent 
(Invitrogen). Reverse transcription was performed with M-MLV Reverse Transcriptase (Sigma-Aldrich) 
and random nonamers (Sigma-Aldrich) primers. Real-time PCR reactions were carried out in Step One 
Plus real-time cycler (Applied-Biosystem, NY, USA) using Taq Polimerase (Sigma-Aldrich) and SYBR 
green. Gene expression was quantified by the comparative cycle threshold method (Δ Δ CT) and nor-
malized using the housekeeping gene TATA binding protein (TBP). Melting curves were used to monitor 
unspecific amplification products.
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